Moreover, compared to low expression, high HMGB1 expression was associated with a poorer response to CRT, in terms of both the tumor reduction ratio (42.2 versus 28.9%, respectively; P <0.01) and the post-CRT histological tumor regression grade (43.5 versus 69.2% and 56.5 versus 30.8%, respectively for grades 1 and 2; P = 0.03). This evidence concerns the gene HMGB1 and neoplasm.